Answers are grounded in this paper and cite their sources.
To compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and camrelizumab or with sorafenib alone in patients with intermediate or advanced hepatocellular carcinoma (HCC).
No takes yet. Share an insight, caveat, or question.
Sun et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: